Bevacizumab (Avastin) is a blocking antibody to VEGF is approved in combination with chemotherapy to treat metastatic colorectal cancer, non-small-cell lung cancer, and breast cancer [160]. The gene discussed is VEGFA; the disease is metastatic colorectal cancer.